Valuation: Stereotaxis, Inc.

Market Cap 176M 154M 142M 132M 250M 16.85B 255M 1.71B 665M 8.24B 661M 646M 28.62B P/E 2026 *
-9x
P/E 2027 * -12x
Enterprise Value 176M 154M 142M 132M 250M 16.85B 255M 1.71B 665M 8.24B 661M 646M 28.62B EV / Sales 2026 *
4.47x
EV / Sales 2027 * 3.3x
Free-Float
84.41%
Yield 2026 *
-
Yield 2027 * -
1 day-1.10%
1 week+1.69%
Current month+4.65%
1 month-0.55%
3 months-6.74%
6 months-30.23%
Current year-21.74%
1 week 1.77
Extreme 1.7701
1.94
1 month 1.59
Extreme 1.59
1.98
Current year 1.59
Extreme 1.59
2.86
1 year 1.59
Extreme 1.59
3.59
3 years 1.33
Extreme 1.33
3.59
5 years 1.33
Extreme 1.33
10.08
10 years 0.47
Extreme 0.47
10.3
Manager TitleAgeSince
Chief Executive Officer - 2017-02-02
Director of Finance/CFO 57 2019-09-30
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 79 2005-01-31
Chairman - 2017-02-02
Director/Board Member 71 2016-09-28
Date Insider Type Main position Quantity % Market Cap.
06-30
DAFNA Capital Management LLC
OtherCompany 0 0%
06-30Free

Director

43,103 0.0441%
06-30Free

Director

43,103 0.0441%
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%+1.69%-17.81%+20.81% 178M
-1.26%-0.62%+19.70%-0.70% 192B
-2.86%+3.16%-21.28%+25.30% 151B
-1.76%-1.52%-4.94%-18.15% 137B
-1.08%+4.06%-56.24%-14.30% 67.33B
-1.24%+1.79%+22.58%+3.74% 54.6B
-2.84%-0.67%-26.99%-30.92% 44.94B
-1.58%-3.24%+6.66%+10.32% 37.04B
-1.81%-2.64%+5.85%+39.36% 36.81B
-6.33%+2.36%-19.78%-4.62% 31.7B
Average -2.19%+2.45%-9.22%+3.08% 75.34B
Weighted average by Cap. -2.01%+2.48%-5.38%+0.98%

Financials

2026 *2027 *
Net sales 39.4M 34.56M 31.9M 29.48M 55.88M 3.77B 57M 384M 149M 1.85B 148M 145M 6.41B 53.28M 46.73M 43.14M 39.87M 75.56M 5.1B 77.07M 519M 202M 2.5B 200M 196M 8.67B
Net income -19.4M -17.02M -15.71M -14.52M -27.52M -1.86B -28.07M -189M -73.38M -909M -72.85M -71.26M -3.16B -13.62M -11.95M -11.03M -10.2M -19.32M -1.3B -19.71M -133M -51.54M -638M -51.17M -50.04M -2.22B
Net Debt - -
Logo Stereotaxis, Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.
Employees
131
Date Price Change Volume
26-07-08 US$1.800 -1.10% 879,909
26-07-07 US$1.820 -3.70% 962,442
26-07-06 US$1.890 +5.59% 950,954
26-07-02 US$1.790 +1.13% 229,519
26-07-01 US$1.770 +2.91% 461,597
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.800USD
Average target price
4.125USD
Spread / Average Target
+129.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STXS Stock